HDAC6 and B-cell chronic lymphocytic leukemia: In the current study, we therefore sought to investigate the immunomodulatory role of HDAC6 in CLL and test the rational combination of a selective HDAC6 inhibitor with PD-1/PD-L1 blockade in the Eμ-TCL1 adoptive transfer model of murine CLL.